WHO Pharmaceuticals Newsletter 1999, No. 03&04
(1999; 16 pages)
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory actions
Cerrar esta carpetaDrug surveillance
Ver el documentoACE inhibitors: survey of renal monitoring: UK
Ver el documentoAcenocoumarol: alopecia: Spain
Ver el documentoAnti-thyroid drugs: agranulocytosis: UK
Ver el documentoCannabis: two clinical trials to start soon: UK
Ver el documentoClozapine: gastrointestinal obstruction: UK
Ver el documentoDonepezil: review of adverse reactions: seizure and heart block: UK
Ver el documentoDrugs and children: ADR reporting: new rules for paediatric trials of medicines: unlicensed drug use in neonates: UK
Ver el documentoErgotamine: interaction with HIV protease inhibitors: France, Switzerland
Ver el documentoFexofenadine: cardiac reaction: Netherlands
Ver el documentoInhaled corticosteroids: peri-oral dermatitis: Israel
Ver el documentoMirtazepine: intrahepatic cholestasis: Finland
Ver el documentoNicorandil: mouth ulcers: France
Ver el documentoOrlistat: caution against nonprescription use: UK
Ver el documentoSildenafil: interaction with HIV protease inhibitors: UK
Ver el documentoSucralfate: bezoar formation: UK
Ver el documentoTopiramate: transient hemiparesis: UK
Abrir esta carpeta y ver su contenidoNew developments
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Orlistat: caution against nonprescription use: UK

United Kingdom. The manufacturer of the anti-obesity drug orlistat (Xenical: Roche) has advised people against obtaining it other than by a prescription issued by a doctor. The company is concerned about reports that a direct mail company in Jersey has advertised the supply of orlistat without prescription. Orlistat is not intended for people who want to lose weight for cosmetic reasons but for the clinically obese whose weight represents a risk to their health.

The company is working with the Medicines Control Agency to investigate the reports.

Reference: The Pharmaceutical Journal Vol. 261, p. 766, 14 November 1998.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013